Emerging role of adipokines as mediators in atherosclerosis

doi:10.4330/wjc.v2.i11.370

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 11

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7380)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series.

Item

Count

PDF

492

HTML

6589

Figures (1-2)

299

Sum=7380

Nov 26, 2010 (publication date) through Sep 23, 2024

Times Cited of This Article

Times Cited (37)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Cardiol. Nov 26, 2010; 2(11): 370-376
Published online Nov 26, 2010. doi: 10.4330/wjc.v2.i11.370

Full Size Figure Download Figure

Figure 2 An heuristic diagram positing the interplay of adipokines. Visfatin treatment increased the level of interleukin (IL)-6 in circulation. Adiponectin reduced the production of IL-6 and macrophage chemoattractant protein (MCP)-1 by inflamed adipocytes. IL-1β increased the expression of MCP-1 in aortic smooth muscle cells. Thus, the interplay among adipokines may significantly affect the pathogenesis of atherogenesis.

Citation: Zhang H, Cui J, Zhang C. Emerging role of adipokines as mediators in atherosclerosis. World J Cardiol 2010; 2(11): 370-376
URL: https://www.wjgnet.com/1949-8462/full/v2/i11/370.htm
DOI: https://dx.doi.org/10.4330/wjc.v2.i11.370